SCHEMBL4007903

SCHEMBL4007903

Cc1[nH]c2c(C)cccc2c1CCNc1ncnc2cc(-c3ccc(C#N)cc3)sc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17B O94768 1/20 0.42
MAP3K8 P41279 1/20 0.42
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
CCNC P24863 2/20 0.40
CDK8 P49336 2/20 0.40
CDKN1A P38936 1/20 0.40
CDK19 Q9BWU1 1/20 0.40
TYK2 P29597 1/20 0.39
FLT1 P17948 6/20 0.39
EGFR P00533 6/20 0.39
KDR P35968 1/20 0.38
CYP1A2 P05177 4/20 0.37
USP2 O75604 3/20 0.37
CYP3A4 P08684 3/20 0.37
CLK4 Q9HAZ1 3/20 0.37
LMNA P02545 3/20 0.37
CYP2C9 P11712 3/20 0.37
TSHR P16473 3/20 0.37
CYP2D6 P10635 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3939158 0.89 FLT1 (0.48) NPC1RAB9ATYK2FLT1EGFR
SCHEMBL4068884 0.89 TYK2 (0.53) MAP3K8NPC1RAB9ATYK2FLT1
SCHEMBL4076235 0.87 MAP3K8 (0.43) MAP3K8NPC1RAB9ATYK2FLT1
SCHEMBL4072156 0.84 NPC1 (0.42) STK17BMAP3K8NPC1RAB9ACCNC
SCHEMBL13960063 0.84 NPC1 (0.44) STK17BNPC1RAB9ATYK2FLT1
SCHEMBL4008652 0.84 CDK1 (0.41) STK17BMAP3K8NPC1RAB9ATYK2
SCHEMBL3931001 0.84 IKBKB (0.42) MAP3K8NPC1RAB9ATYK2FLT1
SCHEMBL4069817 0.82 CYP1A2 (0.46) FLT1EGFRKDRCYP1A2USP2
SCHEMBL3929417 0.81 STK17B (0.51) STK17BMAP3K8NPC1RAB9AFLT1
SCHEMBL4067376 0.78 FLT1 (0.48) MAP3K8NPC1RAB9ATYK2FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US claimed
WO-2009007421-A1 INDOLYLALKYLTHIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-15 WO claimed
EP-2014662-A1 Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP claimed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
EP-2014662-A1 Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor PTGER2, PTGER1, PTGDR2 STK17B 3100/4885MAP3K8 1818/4885NPC1 2246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.